Inventor · disambiguated record
Nicolas Werbeck
Also filed as: WERBECK NICOLAS
17 granted patents·7 pending applications·36 citations·filing 2016–2022
91Inventor score
Top patents by PatentIndex Score
24 records- 0193US11492358B1Macrocyclic indole derivativesBAYER AG·Filed 2021·Granted Nov 8, 2022·3 cites·18 claims
- 0292US10981932B2Macrocyclic indole derivativesBAYER AG·Filed 2017·Granted Apr 20, 2021·9 cites·17 claims
- 0390US11891404B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2022·Granted Feb 6, 2024·1 cites·10 claims
- 0488US12152041B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2022·Granted Nov 26, 2024·1 cites·6 claims
- 0588US11998539B2Substituted aminoquinolones as DGKalpha inhibitors for immune activationBAYER AG·Filed 2022·Granted Jun 4, 2024·1 cites·24 claims
- 0687US11440923B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2018·Granted Sep 13, 2022·3 cites·15 claims
- 0786US11478451B1Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Oct 25, 2022·3 cites·16 claims
- 0886US11401278B2Macrocyclic indole derivativesBROAD INST INC·Filed 2018·Granted Aug 2, 2022·3 cites·13 claims
- 0985US11447504B2Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Sep 20, 2022·3 cites·14 claims
- 1085US11286263B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2018·Granted Mar 29, 2022·3 cites·9 claims
- 1178US10214542B2Modified macrocyclic compoundsBayer Pharma AG·Filed 2016·Granted Feb 26, 2019·2 cites·27 claims
- 1277US10717749B2Macrocyclic sulfondiimine compoundsBayer Pharma AG·Filed 2016·Granted Jul 21, 2020·2 cites·17 claims
- 1375US11964953B2Substituted aminothiazoles as DGKzeta inhibitors for immune activationBAYER AG·Filed 2022·Granted Apr 23, 2024·0 cites·26 claims
- 1475US11254690B2PTEFb inhibiting macrocyclic compoundsBAYER AG·Filed 2018·Granted Feb 22, 2022·1 cites·22 claims
- 1575US11242356B2PTEFb inhibiting macrocyclic compoundsBAYER AG·Filed 2018·Granted Feb 8, 2022·1 cites·22 claims
- 1667US11691986B2PTEFB inhibiting macrocyclic compoundsBAYER AG·Filed 2021·Granted Jul 4, 2023·0 cites·20 claims
- 1765US2022281892A1Novel ptefb inhibiting macrocyclic compoundsBAYER AG·Filed 2022·Application pending·0 cites
- 1862US2023167078A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 1960US2023167103A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 2057US12478621B2Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Granted Nov 25, 2025·0 cites·17 claims
- 2150US2023064809A1Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Application pending·0 cites
- 2248US2023062100A1Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Application pending·0 cites
- 2348US2023072421A1Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancerBAYER AS·Filed 2020·Application pending·0 cites
- 2443US2021253598A1Aryl annulated macrocyclic indole derivativesBAYER AG·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nicolas Werbeck files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →